Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gain Therapeutics (GANX) EBT (2020 - 2025)

Gain Therapeutics has reported EBT over the past 6 years, most recently at $18.0 million for Q4 2025.

  • Quarterly results put EBT at $18.0 million for Q4 2025, up 651.82% from a year ago — trailing twelve months through Dec 2025 was $3.2 million (up 115.98% YoY), and the annual figure for FY2025 was $3.2 million, up 115.98%.
  • EBT for Q4 2025 was $18.0 million at Gain Therapeutics, up from -$4.7 million in the prior quarter.
  • Over the last five years, EBT for GANX hit a ceiling of $18.0 million in Q4 2025 and a floor of -$8.1 million in Q2 2024.
  • Median EBT over the past 5 years was -$4.5 million (2022), compared with a mean of -$2.3 million.
  • Biggest five-year swings in EBT: crashed 559.39% in 2021 and later surged 651.82% in 2025.
  • Gain Therapeutics' EBT stood at $3.1 million in 2021, then skyrocketed by 316.95% to $12.7 million in 2022, then plummeted by 136.95% to -$4.7 million in 2023, then skyrocketed by 30.7% to -$3.3 million in 2024, then surged by 651.82% to $18.0 million in 2025.
  • The last three reported values for EBT were $18.0 million (Q4 2025), -$4.7 million (Q3 2025), and -$5.7 million (Q2 2025) per Business Quant data.